Press Releases

MENLO PARK, Calif. — January 13, 2025 — Inquis Medical, a leading innovator in venous thromboembolic disease treatment, today announced completion of patient enrollment in its AVENTUS Clinical Trial, a pivotal Investigational Device Exemption (IDE) trial evaluating the safety and efficacy of the company’s Aventus Thrombectomy System for the treatment of pulmonary embolism (PE).

MENLO PARK, Calif.–(BUSINESS WIRE)–Inquis Medical, a pioneering medical technology company specializing in advanced thrombectomy systems, today announced the successful closure of its $40 million Series B financing round. This oversubscribed round was led by Marshall Wace, a globally recognized investment firm, with strong participation from existing investors, including ShangBay Capital, Yu Star, EnPointe Ventures, and Pierre Lamond. The funding positions Inquis Medical for significant growth and development as it advances its cutting-edge technologies and prepares for commercialization.

What are the key unmet needs with current pulmonary embolism (PE) thrombectomy devices? Dr. Shishehbor: Despite the many advances in the treatment of PE, it remains the third leading cause of cardiovascular death in the United States. Indeed, while mortality has significantly declined with the use of new devices to treat PE, the rate still […]

Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors Redwood City, Calif. – July 12, 2023 – Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the […]